Conditions: 97.9% · liraglutide.
Please show the division. I want to check my own against yours.
I would like the general form as well as the specific number, so I can apply it again.
Where is my error, and what is the correct working?
More usefully, area percentage is not mass percentage, and conflating the two is the most common misreading of a purity figure.
Integration of the shoulder — whether you use perpendicular drop or tangent skim — determines what area gets assigned to the main peak versus the impurity table.
Worth being precise here: column pore size affects mass transfer — a 100 Angstrom packing on a 5 kDa peptide restricts diffusion, broadening the peak and potentially hiding small impurities in the shoulders.
Compare purity within a single laboratory on the same method, never across laboratories.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsPurity is a method-dependent figure, and that is not a limitation of the measurement, it is a property of what the measurement actually answers.
Temperature affects the dynamics of molecular conformation, and if a peptide has proline residues that interconvert on the chromatographic timescale, the peak will split or shoulder at low temperature and collapse at high temperature.
On the detail: mass on column affects detector linearity and peak overlap — overloading broadens peaks and hides neighbours, while underloading improves resolution but loses sensitivity.
Proline conformer interconversion kinetics are well-characterised and the half-life is of the same order as the chromatographic peak width at room temperature.
One qualification: achieving purity above roughly 98 per cent on a 30-residue peptide is fighting the chemistry of synthesis, not the quality of the purification.
If you are ranking vendors, specify a method and have all samples tested at the same place.
The single most important distinction is between what purity measures — the fraction of detected material that is your target — and what you actually want to know — how much of the material in the vial is your target.
Tailing factor measures peak shape, and a badly tailing peak spreads into the region where small impurities live, forcing tangent-skim integration that assigns tail area to the main peak.
Put another way, sample solvent strength affects peak shape — if you inject in strong solvent on a gradient starting in weak solvent, the solvent peak can distort your main peak or create a false shoulder.
The limitation is that single-digit micro-impurities become invisible at typical reporting thresholds, so "no impurities detected" means "none above one in two thousand."
The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.
edited 9 Aug 2025 by bufferline42 — updated for the 2026 guidance change
Gradient slope is the most powerful parameter and almost nobody mentions it, which is why two reports on the same material disagree by a point.
The fraction of your main peak that is actually your target versus isomers, fragments or related sequences is invisible without complementary identity testing.
Inter-laboratory studies on identical peptide material routinely find half-a-per-cent to a full-per-cent spreads in reported purity on the same sample.
Worth noting that method standardisation is poor in the research-grade space compared to pharmaceutical work, so identical-looking methods can produce different results.
Compare purity within a single laboratory on the same method, never across laboratories.
The honest answer is that the achievable range of plausible purity figures for a given vial is wider than most people expect.
Mobile phase additive choice affects ionisation and peak shape — TFA gives sharp peaks but suppresses mass spectrometry signal, formic acid gives worse peaks but preserves signal.
If you are ranking vendors, specify a method and have all samples tested at the same place.
edited 24 Jun 2025 by Dr_Otto_Lindqvist — fixed an arithmetic slip in the third paragraph
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.